• A case of polymyalgia rheumatica complicated with giant thoracic aortic aneurysm with massive intraluminal thrombosis
• A Cautionary Note on Pembrolizumab use in Patients with Ascending Aortic Aneurysms
• A Distinct Instance of Palindromic Rheumatism Disguised as Polymyalgia Rheumatica
• A Movement Classification of Polymyalgia Rheumatica Patients Using Myoelectric Sensors
• Altered Plasma Levels and Tissue Expression of Fibroblast Activation Protein Alpha in Giant Cell Arteritis
• ANCA-associated vasculitis with muscle involvement mimicking polymyalgia rheumatica
• Anti-interleukin-6 receptor antibody for the treatment of remitting seronegative symmetrical synovitis with pitting oedema: a new outlook?
• Antiplatelet therapy to prevent ischemic events in giant cell arteritis: protocol for a systematic review and meta-analysis
• Association between sinusitis and incident rheumatic diseases: a population-based study
• Association of clinical, imaging and laboratory parameters with adverse effects of glucocorticoid therapy in patients with giant cell arteritis
• Broadening the clinical spectrum of giant cell arteritis: from the classic cranial to the predominantly extracranial pattern of the disease
• Cannabis therapy in rheumatological diseases: A systematic review
• Case report of transient polymyalgia rheumatica after receiving the first dose of the BNT162b2 mRNA COVID-19 vaccine
• Characterising polymyalgia rheumatica on whole-body (18)F-FDG PET/CT: an atlas
• Characterising polymyalgia rheumatica on whole-body ¹⁸F-FDG PET/CT: an atlas
• Characteristics of emerging new autoimmune diseases after COVID-19 vaccination: A sub-study by the COVAD group
• Chinese expert consensus on off-label use of Tocilizumab in rheumatic diseases
• Clinical characteristics and courses of Korean patients with giant cell arteritis: a multi-center retrospective study
• Clinical Manifestations and Prognosis of Giant Cell Arteritis: A Retrospective Cohort Study
• Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement
• Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Reply
• Concomitant Polymyalgia Rheumatica and Giant Cell Arteritis Associated with Cystic Echinococcosis: A Rare Geriatric Case
• Concomitant pyogenic spondylodiscitis and empyema following tongue cancer resection and wisdom tooth extraction: A case report and literature review
• Concordance and agreement between different activity scores in polymyalgia rheumatica
• Correction to: Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study
• De novo Connective Tissue Disorders as Immune-related Adverse Events
• Definitions of and Instruments for Disease Activity, Remission, and Relapse in Polymyalgia Rheumatica: A Systematic Literature Review
• Diagnosing vasculitis with ultrasound: findings and pitfalls
• Diagnostic accuracy of serum biomarkers to identify giant cell arteritis in patients with polymyalgia rheumatica
• Did the first description of patients with polymyalgia rheumatica take place in Scotland or in Denmark?
• Effectiveness of methotrexate and leflunomide as corticoid-sparing drugs in patients with polymyalgia rheumatica
• Efficacy and Safety of Biologics in Polymyalgia Rheumatica: A Retrospective Study
• Global burden of vaccine-associated rheumatic diseases and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database
• Ibuprofen Would Be the First-Line Nonsteroidal Anti-inflammatory Drug for Polymyalgia Rheumatica: A Case Series of Five Patients
• Identifying Giant Cell Arteritis patients with higher risk of relapse and vascular events: a cluster analysis
• Imaging evaluation of hip capsule disorders: a comprehensive review
• Imaging findings in Giant Cell Arteritis: Don't Turn A Blind Eye To The Obvious!
• Imaging in Rheumatic Immune-related Adverse Events
• Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management
• Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica
• Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement
• Immune checkpoints in autoimmune vasculitis
• Improved Diagnostic Accuracy for Polymyalgia Rheumatica using FDG-PET/CT with Clinical Diagnosis or 2012 ACR/EULAR Classification Criteria
• Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study
• Integrating point of care ultrasound into rheumatology practice
• Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development
• Large vessel vasculitis is a risk factor for relapse only in giant cell arteritis patients without polymyalgia rheumatica
• Leflunomide as a therapeutic alternative to methotrexate as a glucocorticoid-sparing agent in polymyalgia rheumatica
• Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Patients With Chronic Inflammatory Disease
• Low incidence of late-onset giant cell arteritis during the first year in patients with polymyalgia rheumatica-a repeated imaging study
• Low incidence of malignancy in patients with suspected polymyalgia rheumatica or giant cell arteritis, examined with FDG-PET/CT
• Medication error with methotrexate
• Modifiable risk factors and inflammation-related proteins in polymyalgia rheumatica: genome-wide meta-analysis and Mendelian randomisation
• Mortality associated with polymyalgia rheumatica in the United States in the 1999-2020 period: a multiple-cause-of-death study
• MRI of shoulder girdle in polymyalgia rheumatica: inflammatory findings and their diagnostic value
• Naive Inflammatory Proteome Profiles of Glucocorticoid Responsive Polymyalgia Rheumatica and Rheumatic Arthritis Patients-Links to Triggers and Proteomic Manifestations
• Newer Therapies in Rheumatology
• Nurses' roles, interventions, and implications for management of rheumatic diseases
• Outcomes of polymyalgia rheumatica in real-world practice: a longitudinal cohort study
• Polymyalgia Rheumatica After COVID-19 Vaccination: Data from the EudraVigilance Database
• Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey
• Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms
• Polymyalgia Rheumatica During the Course of Limited Cutaneous Scleroderma: An Unusual and Challenging Coexistence
• Polymyalgia Rheumatica Following Respiratory Syncytial Virus (RSV) Vaccination
• Polymyalgia rheumatica is a risk factor for more recalcitrant disease in giant cell arteritis: A retrospective cohort study
• Polymyalgia Rheumatica Post-SARS-CoV-2 Infection
• Polymyalgia rheumatica shows metabolomic alterations that are further altered by glucocorticoid treatment: Identification of metabolic correlates of fatigue
• Polymyalgia rheumatica: What's new?
• Positron Emission Tomography/Computed Tomography in Polymyalgia Rheumatica: When and for What-A Critical Review
• Prevalence, characteristics, and outcome of subclinical vasculitis in polymyalgia rheumatica: a retrospective cohort study
• Recommendations for defining giant cell arteritis fast-track clinics
• Recommendations for defining giant cell arteritis fast-track clinics. English version
• Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica
• Referral of patients with suspected polymyalgia rheumatica: how complete is our view of 'planet PMR?'
• Remitting Seronegative Symmetrical Synovitis With Pitting Oedema Associated With Malignancy: A Case Report
• Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy
• Rheumatology: What You May Have Missed in 2023
• Role and potential of ¹⁸F-fluorodeoxyglucose-positron emission tomography-computed tomography in large-vessel vasculitis: a comprehensive review
• Sarilumab (Kevzara) for polymyalgia rheumatica
• Serum protein profiling reveals distinct patient clusters in giant cell arteritis
• Should all patients with polymyalgia rheumatica have a vascular ultrasound assessment?
• Subclinical Aortic Inflammation in Patients with Polymyalgia Rheumatica
• Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica: Is Vascular Imaging Really Ready to Determine Steroid Dosing?
• Submacular and Intraretinal Fluid Associated with Arteritic Anterior Ischemic Optic Neuropathy
• Supra-aortal intima-media thickness in treatment-naive polymyalgia patients compared to matched controls
• The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities
• The DANIsh VASculitis cohort study: protocol for a national multicenter prospective study including incident and prevalent patients with giant cell arteritis and polymyalgia rheumatica
• The effect of prednisolone and a short-term prednisolone discontinuation for the diagnostic accuracy of FDG-PET/CT in polymyalgia rheumatica-a prospective study of 101 patients
• The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials
• The relationship between large vessel vasculitis and glucocorticoid responsiveness of musculoskeletal inflammation: An unverified issue on polymyalgia rheumatica
• The relationship between obesity and patient-reported outcome measures in people with polymyalgia rheumatica
• The risk and risk factors of chikungunya virus infection and rheumatological sequelae in a cohort of U.S. Military Health System beneficiaries: Implications for the vaccine era
• The spectrum of giant cell arteritis through a rheumatology lens
• The utility of (18)F-FDG-PET/CT in detecting extracranial large vessel vasculitis in rheumatic polymyalgia or giant cell arteritis: A systematic review and meta-analysis
• The utility of (18)F-FDG-PET/CT in detecting extracranial large vessel vasculitis in rheumatic polymyalgia or giant cell arteritis. A systematic review and meta-analysis
• The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events
• Time to flare in giant cell arteritis and polymyalgia rheumatica: analysis from a single-centre Australian practice
• Treatment of polymyalgia rheumatica: British Society for Rheumatology guideline scope
• Vitamin D and Muscle Status in Inflammatory and Autoimmune Rheumatic Diseases: An Update
• What Is Polymyalgia Rheumatica?